Beeline Medicines

Stub active Updated Apr 16, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Founded 2025
Latest Stage Series A
Total Raised $300M
Sector
biotech immunology

Investors

bain-capital series-a (2026)

Founders

Saqib Islam CEO

About

Beeline Medicines is a clinical-stage biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases 1. The company was formed in July 2025 as a spinout from Bristol Myers Squibb backed by Bain Capital, and publicly debuted on April 15, 2026 2. Beeline’s initial portfolio comprises five programs in-licensed from BMS, led by afimetoran, a selective TLR7/8 inhibitor granted FDA Fast Track Designation for systemic lupus erythematosus 1. CEO Saqib Islam previously led SpringWorks Therapeutics before its $3.4 billion acquisition by Merck KGaA 2.

Funding History

Date Round Amount Lead Co-investors
2026-04-15 Series A $300M Bain Capital — 12

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. GlobeNewsWire, “Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases,” April 15, 2026. https://www.globenewswire.com/news-release/2026/04/15/3274299/0/en/Beeline-Medicines-Debuts-to-Deliver-Category-Leading-Precision-Therapies-for-People-Living-with-Autoimmune-and-Inflammatory-Diseases.html↩↩↩

  2. BioSpace, “BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut,” April 15, 2026. https://www.biospace.com/business/bms-makes-a-beeline-bringing-5-assets-to-biotechs-300m-precision-immunology-debut↩↩↩